Start your engines, investors! On January 31st, we have three high-flying stocks for you to consider. These stocks have strong momentum and a buy rank. So, grab your seatbelts and let’s dive into why you should pay attention to these opportunities:
ADMA Biologics, Inc.
First up, we have ADMA Biologics, Inc. This biopharmaceutical company has been setting the pace with a Zacks Rank #1 and a remarkable 33.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days. ADMA’s shares have surged an impressive 52% in the last three months, leaving the S&P 500’s 16.1% advance in the dust. With a Momentum Score of A, this biotech player is shooting for the stars.
ADMA Biologics Inc Price and Consensus
ADMA Biologics Inc price-consensus-chart | ADMA Biologics Inc Quote
ADMA Biologics Inc Price
ADMA Biologics Inc price | ADMA Biologics Inc Quote
Ekso Bionics Holdings, Inc.
Next on the grid, we have Ekso Bionics Holdings, Inc. This company specializing in exoskeleton products is keeping up with ADMA with a Zacks Rank #1 and a 25.6% surge in the Zacks Consensus Estimate for its current year earnings over the last 60 days. Ekso Bionics’ shares have sprinted ahead by 56.9% in the last three months, flexing its muscles against the S&P 500’s 16.1% advance. With a Momentum Score of A, this stock is a force to be reckoned with.
Ekso Bionics Holdings, Inc. Price and Consensus
Ekso Bionics Holdings, Inc. price-consensus-chart | Ekso Bionics Holdings, Inc. Quote
Ekso Bionics Holdings, Inc. Price
Ekso Bionics Holdings, Inc. price | Ekso Bionics Holdings, Inc. Quote
Inhibikase Therapeutics, Inc.
Last but not least, we have Inhibikase Therapeutics, Inc. This clinical-stage pharmaceutical company is revving up with a Zacks Rank #1 and a solid 16% surge in the Zacks Consensus Estimate for its current year earnings over the last 60 days. Inhibikase’s shares have taken pole position with an astounding 270.6% surge in the last three months, outpacing the S&P 500’s 16.1% advance. With a Momentum Score of B, this company is a dark horse worth betting on.
Inhibikase Therapeutics, Inc. Price and Consensus
Inhibikase Therapeutics, Inc. price-consensus-chart | Inhibikase Therapeutics, Inc. Quote
Inhibikase Therapeutics, Inc. Price
Inhibikase Therapeutics, Inc. price | Inhibikase Therapeutics, Inc. Quote
Ready to rev up your portfolio? Check out the complete list of top-ranked stocks here.
Learn more about the Momentum score and how it is calculated here.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
Want the latest recommendations from Zacks Investment Research? Download the 7 Best Stocks for the Next 30 Days.
ADMA Biologics Inc Free Stock Analysis Report
Ekso Bionics Holdings, Inc. Free Stock Analysis Report
Inhibikase Therapeutics, Inc. Free Stock Analysis Report